Research programme: CD8 antagonists - MediGene

Drug Profile

Research programme: CD8 antagonists - MediGene

Alternative Names: YourDex

Latest Information Update: 30 Aug 2010

Price : $50

At a glance

  • Originator Avidex
  • Developer MediGene Ltd
  • Class Proteins
  • Mechanism of Action CD8 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Psoriasis; Transplant rejection

Most Recent Events

  • 12 Dec 2007 Preclinical trials in Transplant rejection in United Kingdom (Parenteral)
  • 12 Dec 2007 Preclinical trials in Psoriasis in United Kingdom (Parenteral)
  • 29 Sep 2006 Avidex is acquired by MediGene AG
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top